NASDAQ · Biotechnology

CLDX (CLDX) Stock

$35.80 +0.63% NASDAQ: CLDX Healthcare

Valuation

MetricValue
Price$35.80
Market Cap$2.38B
P/E Ratio-7.84
P/B Ratio3.86
P/S Ratio2493.57
EPS (TTM)$0.00
52-Week High$40.24
52-Week Low$17.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-49.15%
ROA-44.43%
ROCE-54.46%
Gross Margin-14350.00%
Operating Margin-14350.00%
Net Margin-345.96%
Debt/Equity0.00
Current Ratio10.49

Annual Financials (USD)

Metric20212022202320242025
Revenue$5.0M$2.0M$7.0M$7.0M$2.0M
Operating Profit$-71.0M$-115.0M$-155.0M$-195.0M$-287.0M
Net Profit$-71.0M$-112.0M$-141.0M$-158.0M$-259.0M
EPS$-1.64$-2.40$-2.92$-2.45$-3.90
Op Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$445.0M$353.0M$466.0M$792.0M$583.0M
Total Liabilities$25.0M$27.0M$36.0M$45.0M$56.0M
Cash$39.0M$29.0M$35.0M$28.0M$29.0M
Borrowings$3.0M$4.0M$3.0M$4.0M$2.0M

Latest News

Celldex Therapeutics CFO Plans to Retire in 2027 MT Newswires · Jul 15, 2026 Celldex Announces Planned Transition of Chief Financial Officer GlobeNewswire · Jul 15, 2026 Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? Insider Monkey · Jun 30, 2026 Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight PR Newswire · Jun 24, 2026 QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now InvestorPlace · Jun 19, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-61.0M$-104.0M$-107.0M$-158.0M$-211.0M
Investing Cash Flow$-217.0M$88.0M$-108.0M$-292.0M$206.0M
Financing Cash Flow$2.0M$0$2.0M$9.0M$0
Net Cash Flow$-5.0M$-10.0M$5.0M$-6.0M$1.0M
Free Cash Flow$-62.0M$-106.0M$-109.0M$-160.0M$-214.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-11.05%
Quick Ratio8.92
Interest Coverage—
Return 1Y55.50%
Return 3Y-4.50%
Return 5Y-18.38%

Ownership

Insiders Held0.27%
Institutions Held95.89%
Institutions Float Held96.15%
Institutional HolderSharesReport Date
Wellington Management Group, LLP8,560,4762026-03-31
Kynam Capital Management, LP5,840,5672026-03-31
Blackrock Inc.5,369,8852026-03-31
FMR, LLC3,749,0482026-03-31
Point72 Asset Management, L.P.3,229,9392026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $6.93 +6.13% -5.91 $2.12B 0.00%
BHVN $14.07 +3.19% -6.11 $2.12B 0.00%
HRMY $38.24 -1.39% 11.23 $2.21B 0.00%
IMNM $23.22 +2.83% -8.13 $2.22B 0.00%
JANX $16.04 +0.25% -7.78 $978.19M 0.00%

About CLDX

CLDX stock trades at $35.80 with a market capitalization of $2.38B. The stock is valued at a price-to-earnings (P/E) ratio of -7.84, price-to-book of 3.86, price-to-sales of 2493.57. Over the past 52 weeks the stock has ranged between $17.85 and $40.24, and currently trades 11.0% below its 52-week high.

On profitability, CLDX generates a return on equity (ROE) of -49.15%, return on capital employed of -54.46%, an operating margin of -14350.00%, a net profit margin of -345.96%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides